Optimising adherence and QoL in metastatic NSCLC
Epidermal growth factor receptor tyrosine kinase inhibitors are widely used in the management of metastatic non-small cell lung cancer. Adverse events, their impact on quality of life and treatment adherence with these oral drugs are discussed
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer